Metharbital
From Wikipedia, the free encyclopedia
Metharbital
|
|
Systematic (IUPAC) name | |
5,5-diethyl-1-methyl-hexahydropyrimidine-2,4,6-trione | |
Identifiers | |
CAS number | |
ATC code | N03 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C9H14N2O3 |
Mol. mass | 198.219 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Metharbital was patented in 1905 by Emil Fischer working for Merck[1]. It was marketed as Gemonil by Abbott Laboratories. It is a barbiturate anticonvulsant, used in the treatment of epilepsy. It has similar properties to phenobarbital.
[edit] History
- 1952 Gemonil was introduced by Abbott Laboratories.
- 1990 Abbott stopped marketing.
[edit] References
- The Treatment of Epilepsy 2nd Ed by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. ISBN 0-632-06046-8
- The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5.
- The Comparative Toxicogenomics Database: Metharbital
- ^ US Patent 782742
|